Beginning November 1st, you’ll be able to find Retrogenix technology information and content at our new home in Discovery on the Charles River website (criver.com).
The leading solution for receptor identification and off-target screening
Respected globally, Retrogenix’s clients include the world’s top twenty pharma
Uncover primary receptors and off-targets
Retrogenix’s cell microarray technology is the most powerful solution for identifying the specific human plasma membrane and secreted proteins that are targeted by antibodies, proteins, small molecules, viruses, CAR T cells and other ligands. We discover high quality, exploitable drug targets and mechanisms of action for our global pharmaceutical clients as well as screening for potential off-targets to inform lead selection and generate high quality IND-enabling specificity data.
- High success rates
- High specificity
- Low false positive rates
- Rapid turnaround (as little as 3 weeks)
Our unrivalled technology identifies interactions both with cell surface receptors and secreted proteins by screening test ligands for binding against over 6,200 full length proteins that are individually over-expressed in human cells. This physiologically-relevant system, coupled with our broad protein coverage, allows even low affinity interactions to be detected with a high degree of sensitivity and specificity.
Retrogenix, a Charles River company, works with small biotechs and leading academic groups through to major pharmaceutical companies; we are currently helping the world’s top twenty drug developers to bring new therapeutics to market faster.